Intravitreal bevacizumab for macular edema due to central retinal vein occlusion: perfused vs. ischemic and early vs. late treatment.
Publication
, Journal Article
Fekrat, S; DeCroos FC, ; Ehlers JP, ; Stinnett S,
Published in: Current Eye Research
2011
Duke Scholars
Published In
Current Eye Research
Publication Date
2011
Volume
36
Start / End Page
1164 / 1170
Related Subject Headings
- Ophthalmology & Optometry
Citation
APA
Chicago
ICMJE
MLA
NLM
Fekrat, S., DeCroos FC, ., Ehlers JP, ., & Stinnett S, . (2011). Intravitreal bevacizumab for macular edema due to central retinal vein occlusion: perfused vs. ischemic and early vs. late treatment. Current Eye Research, 36, 1164–1170.
Fekrat, S., S. DeCroos FC, S. Ehlers JP, and S. Stinnett S. “Intravitreal bevacizumab for macular edema due to central retinal vein occlusion: perfused vs. ischemic and early vs. late treatment.” Current Eye Research 36 (2011): 1164–70.
Fekrat S, DeCroos FC, Ehlers JP, Stinnett S. Intravitreal bevacizumab for macular edema due to central retinal vein occlusion: perfused vs. ischemic and early vs. late treatment. Current Eye Research. 2011;36:1164–70.
Fekrat, S., et al. “Intravitreal bevacizumab for macular edema due to central retinal vein occlusion: perfused vs. ischemic and early vs. late treatment.” Current Eye Research, vol. 36, 2011, pp. 1164–70.
Fekrat S, DeCroos FC, Ehlers JP, Stinnett S. Intravitreal bevacizumab for macular edema due to central retinal vein occlusion: perfused vs. ischemic and early vs. late treatment. Current Eye Research. 2011;36:1164–1170.
Published In
Current Eye Research
Publication Date
2011
Volume
36
Start / End Page
1164 / 1170
Related Subject Headings
- Ophthalmology & Optometry